Itaru Kushima

Itaru Kushima

Auto-generated profile, based on publicly available information

Itaru Kushima

Nagoya University Graduate School of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2020 in Cell
Verified
Journal Article
Closed access
FSF. Kyle Satterstrom
F. Kyle Satterstrom
JKJack A. Kosmicki
Jack A. Kosmicki
JWJiebiao Wang
Jiebiao Wang
MBMichael S. Breen
Michael S. Breen
SRSilvia De Rubeis
Silvia De Rubeis
JBJoseph D. Buxbaum
Joseph D. Buxbaum

17 July 2017 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
ELElaine Lim
Elaine Lim
MUMohammed Uddin
Mohammed Uddin
SRSilvia De Rubeis
Silvia De Rubeis
YCYingleong Chan
Yingleong Chan
AKAnne S Kamumbu
Anne S Kamumbu
CWChristopher A Walsh
Christopher A Walsh
Survey of postzygotic mosaic mutations (PZMs) in 5,947 trios with autism spectrum disorders (ASD) discovers differences in mutational properties between germline mutations and PZMs. Spatiotemporal analyses of the PZMs also revealed the association of the amygdala with ASD and implicated risk genes, including recurrent potential gain-of-function mutations in SMARCA4. We systematically analyzed postzygotic mutations (PZMs) in whole-exome sequences from the largest collection of trios (5,947) with autism spectrum disorder (ASD) available, including 282 unpublished trios, and performed resequencing using multiple independent technologies. We identified 7.5% of de novo mutations as PZMs, 83.3% of which were not described in previous studies. Damaging, nonsynonymous PZMs within critical exons of prenatally expressed genes were more common in ASD probands than controls (P < 1 × 10−6), and genes carrying these PZMs were enriched for expression in the amygdala (P = 5.4 × 10−3). Two genes (KLF16 and MSANTD2) were significantly enriched for PZMs genome-wide, and other PZMs involved genes (SCN2A, HNRNPU and SMARCA4) whose mutation is known to cause ASD or other neurodevelopmental disorders. PZMs constitute a significant proportion of de novo mutations and contribute importantly to ASD risk.

1 September 2018 in Cell Reports
Verified
Journal Article
Open access
IKItaru Kushima
Itaru Kushima
Branko AleksicBranko Aleksic
Branko Aleksic
MNMasahiro Nakatochi
Masahiro Nakatochi
TSTeppei Shimamura
Teppei Shimamura
TOTakashi OKADA
Takashi OKADA
NONorio Ozaki
Norio Ozaki
Compelling evidence in Caucasian populations suggests a role for copy-number variations (CNVs) in autism spectrum disorder (ASD) and schizophrenia (SCZ). We analyzed 1,108 ASD cases, 2,458 SCZ cases, and 2,095 controls in a Japanese population and confirmed an increased burden of rare exonic CNVs in both disorders. Clinically significant (or pathogenic) CNVs, including those at 29 loci common to both disorders, were found in about 8% of ASD and SCZ cases, which was significantly higher than in controls. Phenotypic analysis revealed an association between clinically significant CNVs and intellectual disability. Gene set analysis showed significant overlap of biological pathways in both disorders including oxidative stress response, lipid metabolism/modification, and genomic integrity. Finally, based on bioinformatics analysis, we identified multiple disease-relevant genes in eight well-known ASD/SCZ-associated CNV loci (e.g., 22q11.2, 3q29). Our findings suggest an etiological overlap of ASD and SCZ and provide biological insights into these disorders.

1 March 2011 in Biological Psychiatry
Verified
Journal Article
Closed access
MIMasashi Ikeda
Masashi Ikeda
BABranko Aleksic
Branko Aleksic
YKYoko Kinoshita
Yoko Kinoshita
TOTomo Okochi
Tomo Okochi
KKKunihiro Kawashima
Kunihiro Kawashima
NINakao Iwata
Nakao Iwata

1 January 2018 in Cell Reports
Verified
Journal Article
Open access
ATAtsushi Takata
Atsushi Takata
NMNoriko Miyake
Noriko Miyake
YTYoshinori Tsurusaki
Yoshinori Tsurusaki
RFRyoko Fukai
Ryoko Fukai
SMSatoko Miyatake
Satoko Miyatake
NMNaomichi Matsumoto
Naomichi Matsumoto
Recent studies have established important roles of de novo mutations (DNMs) in autism spectrum disorders (ASDs). Here, we analyze DNMs in 262 ASD probands of Japanese origin and confirm the "de novo paradigm" of ASDs across ethnicities. Based on this consistency, we combine the lists of damaging DNMs in our and published ASD cohorts (total number of trios, 4,244) and perform integrative bioinformatics analyses. Besides replicating the findings of previous studies, our analyses highlight ATP-binding genes and fetal cerebellar/striatal circuits. Analysis of individual genes identified 61 genes enriched for damaging DNMs, including ten genes for which our dataset now contributes to statistical significance. Screening of compounds altering the expression of genes hit by damaging DNMs reveals a global downregulating effect of valproic acid, a known risk factor for ASDs, whereas cardiac glycosides upregulate these genes. Collectively, our integrative approach provides deeper biological and potential medical insights into ASDs.

29 June 2018 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
HYHidenori Yamasue
Hidenori Yamasue
TOTakashi OKADA
Takashi OKADA
TMToshio Munesue
Toshio Munesue
MKMiho Kuroda
Miho Kuroda
TFToru Fujioka
Toru Fujioka
HKHirotaka Kosaka
Hirotaka Kosaka